ClinicalTrials.gg
TerminatedNCT03472326Updated Jan 5, 2021Results posted

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

A Phase 2 interventional study of GS-9131 and BIC in HIV-1-infection, sponsored by Gilead Sciences. Terminated at 2 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
GS-9131 did not meet the targeted antiviral response

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The primary objective of this study is to evaluate the short-term antiviral potency of GS-9131 functional monotherapy compared to placebo-to-match (PTM) GS-9131, each administered once daily with the existing failing antiretroviral (ARV) regimen as demonstrated by the proportion of participants achieving human immunodeficiency virus ribonucleic acid (HIV-1 RNA) > 0.5 log10 decreases from baseline after up to 14 days of therapy in HIV-1 positive, ARV treatment experienced adult participants with nucleos(t)ide resistant virus.

This is a two-part study. Part 1 consists of three cohorts: 2 Sentinel Cohorts and 1 Randomized Cohort. Eligible participants from Part 1 will proceed to Part 2 followed by an optional open-label extension.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Plasma -1 RNA ≥ 500 copies/mL at screening Visit
  • Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI
  • No prior or current ARV regimens containing integrase inhibitor (INSTI) or protease inhibitor (PI)
  • Screening genotype must show at least the protocol defined resistance mutation profile

Key Exclusion Criteria:

  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1
  • Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial
  • Use of an drug other than the study drug
  • Individuals with chronic virus (HBV) infection are not permitted to participate
  • Active tuberculosis infection

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Part 1 Sentinel Cohort 1: GS-9131 60 mg

    Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.

    Drug: GS-9131 · Drug: ARV regimen

  • Experimental
    Part 1 Sentinel Cohort 2: GS-9131 180 mg

    Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.

    Drug: GS-9131 · Drug: ARV regimen

  • Experimental
    Part 1: Randomized Cohort

    Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.

    Drug: GS-9131 · Drug: ARV regimen

  • Experimental
    Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV

    Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.

    Drug: GS-9131 · Drug: BIC · Drug: DRV · Drug: RTV

  • Experimental
    Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF

    Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.

    Drug: GS-9131 · Drug: BIC · Drug: TAF

Interventions

  • DrugGS-9131

    Tablet(s) administered orally once daily

  • DrugBIC

    Tablet(s) administered orally once daily

  • DrugTAF

    Tablet(s) administered orally once daily

    Also known as: Vemlidy®

  • DrugARV regimen

    ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)

  • DrugDRV

    Tablet(s) administered orally once daily

    Also known as: Prezista®

  • DrugRTV

    Tablet(s) administered orally once daily

    Also known as: Norvir®

06

What researchers measure

Primary outcomes

  1. Part 1 Randomized Cohort: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 15

    The criteria for analyzing percentage of participants with plasma HIV-1 RNA \> 0.5 log10 decrease from baseline in randomized cohort was at least 50% of the participants should achieve HIV-1 RNA \> 0.5 log10 decrease from baseline in the Part 1 sentinel cohort 2.

    Time frame: Day 15

Secondary outcomes

  1. Part 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11

    Time frame: Baseline, Day 11

  2. Part 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15

    Time frame: Baseline, Day 15

  3. Part 1 Randomized Cohort: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15

    Time frame: Baseline, Day 15

  4. Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  5. Part 2: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24

    Time frame: Baseline, Week 24

  6. Part 2: Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline, Week 24

  7. Part 2: Number of Participants With Treatment Emergent Nucleos(t)Ide Reverse Transcriptase Inhibitor (NRTI) Mutations at the Time of Virologic Failure

    Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.

    Time frame: From first dose up to Week 24

  8. Part 2: Number of Participants With Treatment Emergent Protease Inhibitor (PI) Mutations at the Time of Virologic Failure

    Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.

    Time frame: From first dose up to Week 24

  9. Part 2: Number of Participants With Treatment Emergent Integrase Strand Transfer Inhibitor (INSTI) Mutations at the Time of Virologic Failure

    Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.

    Time frame: From first dose up to Week 24

07

Results

Posted Jan 5, 2021
Limitations and caveats
The study was terminated because a majority of Sentinel Cohort 2 participants did not meet primary endpoint of HIV-1 RNA \> 0.5 log10 decrease from baseline through up to 14 days of therapy.

Participant flow

Participants were enrolled at study sites in Uganda and Zimbawe. The first participant was screened on 03 April 2018. The last study visit occurred on 09 December 2019.

Part 1: GS-9131 Functional Monotherapy
Participant flow — Part 1: GS-9131 Functional Monotherapy
MilestonePart 1 Sentinel Cohort 1: GS-9131 60 mgPart 1 Sentinel Cohort 2: GS-9131 180 mgPart 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTVPart 2 Sentinel Cohort 2: GS-9131 + BIC + TAF
Started111000
Completed111000
Not completed0000
Part 2: Combination Therapy
Participant flow — Part 2: Combination Therapy
MilestonePart 1 Sentinel Cohort 1: GS-9131 60 mgPart 1 Sentinel Cohort 2: GS-9131 180 mgPart 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTVPart 2 Sentinel Cohort 2: GS-9131 + BIC + TAF
Started0013
Completed0000
Not completed0013
Withdrew: Study terminated by sponsor0012
Withdrew: Pregnancy0001

Outcome measures

PrimaryPart 1 Randomized Cohort: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 15

The criteria for analyzing percentage of participants with plasma HIV-1 RNA \> 0.5 log10 decrease from baseline in randomized cohort was at least 50% of the participants should achieve HIV-1 RNA \> 0.5 log10 decrease from baseline in the Part 1 sentinel cohort 2.

Time frame:
Day 15

No measurements were reported for this outcome.

SecondaryPart 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11
Time frame:
Baseline, Day 11
Reported as:
Mean · log10 copies/mL
Part 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11
log10 copies/mLSentinel Cohort 1: GS-9131 60 mg
Part 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11-0.13 ± 0.268
SecondaryPart 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15
Time frame:
Baseline, Day 15
Reported as:
Mean · log10 copies/mL
Part 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15
log10 copies/mLSentinel Cohort 2: GS-9131 180 mg
Part 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15-0.29 ± 0.207
SecondaryPart 1 Randomized Cohort: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15
Time frame:
Baseline, Day 15

No measurements were reported for this outcome.

SecondaryPart 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryPart 2: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24
Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryPart 2: Change From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Treatment Emergent Nucleos(t)Ide Reverse Transcriptase Inhibitor (NRTI) Mutations at the Time of Virologic Failure

Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.

Time frame:
From first dose up to Week 24

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Treatment Emergent Protease Inhibitor (PI) Mutations at the Time of Virologic Failure

Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.

Time frame:
From first dose up to Week 24

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Treatment Emergent Integrase Strand Transfer Inhibitor (INSTI) Mutations at the Time of Virologic Failure

Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.

Time frame:
From first dose up to Week 24

No measurements were reported for this outcome.

Adverse events

Collected over From first dose date up to 30 days after last study drug for Part 1 (Maximum: 44 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Setinel Cohort 1: GS-9131 60 mg0/11 (0%)0/11 (0%)5/11 (45.5%)
Part 1 Sentinel Cohort 2: GS-9131 180 mg0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPart 1 Setinel Cohort 1: GS-9131 60 mgPart 1 Sentinel Cohort 2: GS-9131 180 mg
HypersomniaNervous system disorders0/114/10
Urinary tract infectionInfections and infestations1/113/10
Increased appetiteMetabolism and nutrition disorders0/113/10
DizzinessNervous system disorders0/113/10
DiarrhoeaGastrointestinal disorders0/112/10
NauseaGastrointestinal disorders0/112/10
VomitingGastrointestinal disorders0/112/10
HeadacheNervous system disorders1/112/10
CoughRespiratory, thoracic and mediastinal disorders0/112/10
AnaemiaBlood and lymphatic system disorders1/111/10

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
Mean38 ± 10.737 ± 6.638 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
Female111021
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
Hispanic or Latino000
Not Hispanic or Latino111021
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American111021
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
Uganda11516
Zimbabwe055
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
Mean4.77 ± 0.7034.46 ± 0.5844.62 ± 0.652
HIV-1 RNA Category
HIV-1 RNA Category(Participants)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
< 50 copies/mL000
≥ 50 copies/mL111021
CD4 Cell Count
CD4 Cell Count(cells/µL)Sentinel Cohort 1: GS-9131 60 mgSentinel Cohort 2: GS-9131 180 mgTotal
Mean172 ± 164.1289 ± 140.4228 ± 161.0
08

Study locations

2 sites
  • Joint Clinical Research Centre
    Kampala, 10005, Uganda
  • Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals
    Harare, Zimbabwe
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Dec 2019, 20 months.

Results were first posted in Jan 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2018
First posted
Mar 21, 2018
StartActual
Apr 3, 2018
Primary completionActual
Dec 9, 2019
CompletionActual
Dec 9, 2019
Results first posted
Jan 5, 2021
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03472326
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 21, 2018
Start date
Apr 3, 2018
Primary completion
Dec 9, 2019
Completion
Dec 9, 2019
Results posted
Jan 5, 2021
Last update
Jan 5, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion